Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood Cancer Journal, Published online: 20 February 2024; doi:10.1038/s41408-024-01000-2Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Source: Blood Cancer Journal - February 20, 2024 Category: Hematology Authors: Talha Badar Ahmad Nanaa Ehab Atallah Rory M. Shallis Sacchi de Camargo Correia Guilherme Aaron D. Goldberg Antoine N. Saliba Anand Patel Jan P. Bewersdorf Adam S. DuVall Danielle Bradshaw Yasmin Abaza Guru Subramanian Guru Murthy Neil Palmisiano Amer M. Z Source Type: research